2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Cancer of Endometrium in 13 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Loss of PR increased with disease progression, with 23% of the primary tumours and 76% of metastases demonstrating PR loss." | 1.40 | Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. ( Berg, A; Halle, MK; Hoivik, EA; Krakstad, C; Kusonmano, K; Mills, GB; Salvesen, HB; Tangen, IL; Trovik, J; Werner, HM, 2014) |
| "In most endometrial carcinoma, it has been observed that the PI3K/Akt pathway is abnormally accelerated in association with mutations in PIK3CA and PTEN." | 1.39 | Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS. ( Kitawaki, J; Sakai, T; Yamada, T; Yogosawa, S; Yoshioka, T, 2013) |
| "In vivo endometrial cancer xenograft studies in nude mice also showed that inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer." | 1.37 | Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. ( Chen, X; Feng, Y; Gu, C; Liu, Y; Yin, L; Yu, Y; Zhang, Z; Zhao, F, 2011) |
| "Human endometrial carcinoma Ishikawa cells were cultured in vitro." | 1.37 | [Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice]. ( Guo, RX; Qiao, YH; Shi, HR; Wang, XY; Zhang, RF, 2011) |
| "Although tuberous sclerosis complex 2 (TSC2) is the "gatekeeper" for mTOR activation, little is known about defects in the TSC2 tumor suppressor or signaling pathways that regulate TSC2, such as LKB1/AMP-activated protein kinase, in the development of endometrial carcinoma." | 1.35 | Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. ( Broaddus, RR; Burke, TW; Dave, B; Lu, KH; Munsell, MF; Slomovitz, BM; Walker, CL; Wu, W, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, Y | 1 |
| Dong, Z | 1 |
| Shi, Y | 1 |
| Sun, S | 1 |
| Wei, B | 1 |
| Zhan, L | 1 |
| Yoshioka, T | 1 |
| Yogosawa, S | 1 |
| Yamada, T | 1 |
| Kitawaki, J | 1 |
| Sakai, T | 1 |
| Tangen, IL | 1 |
| Werner, HM | 1 |
| Berg, A | 1 |
| Halle, MK | 1 |
| Kusonmano, K | 1 |
| Trovik, J | 1 |
| Hoivik, EA | 1 |
| Mills, GB | 1 |
| Krakstad, C | 1 |
| Salvesen, HB | 1 |
| Li, Y | 1 |
| Xie, Y | 1 |
| Cui, D | 1 |
| Ma, Y | 1 |
| Sui, L | 1 |
| Zhu, C | 1 |
| Kong, H | 1 |
| Kong, Y | 1 |
| Chen, C | 1 |
| Wang, Y | 1 |
| Wang, S | 1 |
| Liu, Y | 2 |
| Zhang, J | 1 |
| Xu, Y | 1 |
| Zhang, Z | 2 |
| Bao, W | 1 |
| Wu, S | 1 |
| Lin, SL | 1 |
| Yan, LY | 1 |
| Zhang, XT | 1 |
| Yuan, J | 1 |
| Li, M | 1 |
| Qiao, J | 1 |
| Wang, ZY | 1 |
| Sun, QY | 1 |
| Gu, C | 1 |
| Yu, Y | 1 |
| Zhao, F | 1 |
| Yin, L | 1 |
| Feng, Y | 1 |
| Chen, X | 1 |
| Guo, RX | 4 |
| Zhang, RF | 1 |
| Wang, XY | 1 |
| Shi, HR | 1 |
| Qiao, YH | 2 |
| Wei, LH | 3 |
| Wang, JL | 3 |
| Sun, PM | 2 |
| Sun, XL | 1 |
| Zhou, C | 1 |
| Bae-Jump, VL | 1 |
| Whang, YE | 1 |
| Gehrig, PA | 1 |
| Boggess, JF | 1 |
| Tang, JM | 2 |
| Tu, Z | 1 |
| Zhao, D | 1 |
| Li, XP | 1 |
| Lu, KH | 1 |
| Wu, W | 1 |
| Dave, B | 1 |
| Slomovitz, BM | 1 |
| Burke, TW | 1 |
| Munsell, MF | 1 |
| Broaddus, RR | 1 |
| Walker, CL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment[NCT03489473] | 40 participants (Anticipated) | Observational | 2020-01-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Cancer of Endometrium
| Article | Year |
|---|---|
NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Disease Progression; Endometrial Neo | 2020 |
Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis | 2013 |
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Cell Proliferation; Chromones; Disease Progression; Endome | 2014 |
Osteopontin Promotes Invasion, Migration and Epithelial-Mesenchymal Transition of Human Endometrial Carcinoma Cell HEC-1A Through AKT and ERK1/2 Signaling.
Topics: Butadienes; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Endometrial N | 2015 |
LSD1 sustains estrogen-driven endometrial carcinoma cell proliferation through the PI3K/AKT pathway via di-demethylating H3K9 of cyclin D1.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin D1; Endometrial Neoplasms; Estrad | 2017 |
ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
Topics: Alternative Splicing; Antineoplastic Agents, Hormonal; Blotting, Western; Butadienes; Cell Line, Tum | 2010 |
Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; En | 2011 |
[Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice].
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relat | 2011 |
[Activation of phosphatidylinositol 3-kinase-protein kinase B (PI3K-PKB) induced by 17beta-estradiol in endometrial carcinoma cell (Ishikawa)].
Topics: Chromones; Endometrial Neoplasms; Enzyme Activation; Enzyme Inhibitors; Estradiol; Female; Humans; M | 2004 |
The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels.
Topics: Adenoviridae; Cell Growth Processes; Chromones; DNA-Binding Proteins; Endometrial Neoplasms; Enzyme | 2006 |
Blockage of PI3K/PKB/P27kip1 signaling pathway can antagonize 17 beta-estradiol-induced Ishikawa proliferation and cell cycle progression.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin-Dependent Kinase Inhibitor p27; E | 2006 |
17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells.
Topics: Cell Line, Tumor; Chromones; Endometrial Neoplasms; Enzyme Activation; Estradiol; Female; Humans; Mo | 2006 |
Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Topics: AMP-Activated Protein Kinase Kinases; Androstadienes; Cell Line, Tumor; Chromones; Endometrial Neopl | 2008 |